Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications

• click to rate

  Posted by Two Blokes Apr 16 - Filed in Stock - 14 views
  
  SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.